Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripretinib Effect on Repaglinide PK in Advanced GIST
NCT04530981Phase 1Completed
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- Nov 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ripretinib in gastrointestinal stromal tumor (GIST), sponsored by Deciphera Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration for Repaglinide, Area under the concentration-time curve from time 0 up to time t for Repaglinide and 1 more. Started Sep 2021; status: completed.
02
Drugs
ripretinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT04530981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04530981.